TrailBio^® RG108

Brueckner et al. (2005), Cancer Res 

• Identifies RG108 as a DNMT inhibitor that blocks enzyme activity without trapping the enzyme on DNA, demethylating genomic DNA at low micromolar concentrations without detectable toxicity and reactivating silenced tumor suppressor genes. 

Pasha et al. (2011), PLoS One 

• Demonstrates that RG108 treatment reprogrammed mouse skeletal myoblasts into iPS-like cells without exogenous transcription factor delivery, with  resulting cells expressing pluripotency markers and exhibiting cardiomyogenic differentiation potential.  

Assis et al. (2018), PLoS One 

• In human bone marrow mesenchymal stem cells, 50 µM RG108 reduced DNMT activity and global DNA methylation without affecting viability, and epigenetically activated NANOG and OCT4 at their promoters.